Michael K Rowe

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Lithium neuroprotection: molecular mechanisms and clinical implications
    Michael K Rowe
    Molecular Neurobiology Section, National Institute of Mental Health, National Institutes of Health Building 10, Room 4C206, 10 Center Drive, MSC 1363, Bethesda, MD 20892 1363, USA
    Expert Rev Mol Med 6:1-18. 2004
  2. pmc GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder
    Michael K Rowe
    Molecular Neurobiology Section, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Building 10, Room 4C206, 10 Center Drive, MSC 1363, Bethesda, MD 20892 1363, USA
    Neurosci Biobehav Rev 31:920-31. 2007

Collaborators

Detail Information

Publications2

  1. ncbi request reprint Lithium neuroprotection: molecular mechanisms and clinical implications
    Michael K Rowe
    Molecular Neurobiology Section, National Institute of Mental Health, National Institutes of Health Building 10, Room 4C206, 10 Center Drive, MSC 1363, Bethesda, MD 20892 1363, USA
    Expert Rev Mol Med 6:1-18. 2004
    ....
  2. pmc GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder
    Michael K Rowe
    Molecular Neurobiology Section, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Building 10, Room 4C206, 10 Center Drive, MSC 1363, Bethesda, MD 20892 1363, USA
    Neurosci Biobehav Rev 31:920-31. 2007
    ..Taken together, the evidence suggests that targeting GSK-3 may be a means to control the symptoms of bipolar disorder...